VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV

PHASE4CompletedINTERVENTIONAL
Enrollment

3,032

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

July 31, 2021

Study Completion Date

August 31, 2021

Conditions
Smallpox Vaccine Adverse Reaction
Interventions
BIOLOGICAL

Vaccination with ACAM2000

In this study (VA-008), healthy adult male and female volunteers who meet the requirements for source plasma donors and study entry criteria will be vaccinated with the ACAM2000 smallpox vaccine for collection of plasma to be used in the manufacture of VIGIV. There are possible risks associated with ACAM2000 vaccination. To ensure the safety of plasma donors, risk factor screening procedures and the collection of post-vaccination safety data will be assessed throughout the study.

Trial Locations (1)

R3T 5Y3

Bio Products Laboratory Ltd (plasma vendor of Emergent BioSolutions), Winnipeg

Sponsors
All Listed Sponsors
lead

Emergent BioSolutions

INDUSTRY